SG10201701737XA
(en)
|
2003-11-06 |
2017-04-27 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
EP1817336B1
(en)
|
2004-11-12 |
2019-01-09 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
MX2009009912A
(es)
|
2007-03-27 |
2010-01-18 |
Sea Lane Biotechnologies Llc |
Constructos y colecciones que comprenden secuencias de cadena ligera sustitutas de anticuerpos.
|
RU2557319C2
(ru)
|
2007-07-16 |
2015-07-20 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
|
SG183023A1
(en)
|
2007-07-16 |
2012-08-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
JP5727786B2
(ja)
|
2007-10-19 |
2015-06-03 |
シアトル ジェネティクス,インコーポレーテッド |
Cd19結合性物質およびその使用
|
WO2009099728A1
(en)
|
2008-01-31 |
2009-08-13 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
US8163551B2
(en)
|
2008-05-02 |
2012-04-24 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
EP2430047B1
(en)
|
2009-05-13 |
2018-03-28 |
i2 Pharmaceuticals, Inc. |
Neutralizing molecules to influenza viruses
|
EA201792376A3
(ru)
|
2009-10-23 |
2018-08-31 |
Милленниум Фармасьютикалз, Инк. |
Молекулы анти-gcc антитела и соответствующие композиции и способы
|
AU2011213609B2
(en)
*
|
2010-02-08 |
2016-11-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 161P2F10B proteins
|
WO2011109308A1
(en)
|
2010-03-02 |
2011-09-09 |
Seattle Genetics, Inc. |
Methods for screening antibodies
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
KR101950520B1
(ko)
|
2010-08-05 |
2019-02-20 |
시애틀 지네틱스, 인크. |
푸코스 유사체를 사용한 생체 내에서의 단백질 푸코실화 억제 방법
|
JP5884139B2
(ja)
*
|
2010-10-04 |
2016-03-15 |
国立研究開発法人理化学研究所 |
Mhcクラスiiを発現する悪性腫瘍の治療薬
|
ES2730941T7
(es)
|
2010-10-22 |
2020-05-27 |
Seattle Genetics Inc |
Efectos sinérgicos entre los conjugados de conjugados anticuerpo-fármaco a base de auristatina e inhibidores de la ruta PI3K-AKT-mTOR
|
JP5721858B2
(ja)
|
2010-12-23 |
2015-05-20 |
ユーリタ アクチエンゲゼルシャフトEulitha Ag |
大きな面積にわたってナノ構造を製造するためのシステムおよび方法
|
PT2654780T
(pt)
*
|
2010-12-23 |
2017-04-06 |
Janssen Biotech Inc |
Mutantes ativos de fc de anticorpos resistentes a proteases
|
WO2012131527A1
(en)
*
|
2011-04-01 |
2012-10-04 |
Wyeth Llc |
Antibody-drug conjugates
|
MX368966B
(es)
|
2011-06-10 |
2019-10-23 |
Mersana Therapeutics Inc |
Conjugados de proteina-polimero-farmaco.
|
US10300140B2
(en)
|
2011-07-28 |
2019-05-28 |
I2 Pharmaceuticals, Inc. |
Sur-binding proteins against ERBB3
|
ES2909722T3
(es)
|
2011-08-16 |
2022-05-10 |
Morphosys Ag |
Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada
|
SI2744826T1
(sl)
|
2011-08-16 |
2022-05-31 |
Morphosys Ag |
Kombinirana terapija s protitelesom proti CD19 in analogom purina
|
CN102343083A
(zh)
*
|
2011-10-17 |
2012-02-08 |
中国科学院成都生物研究所 |
一种抗病毒的组合药物
|
WO2013067581A1
(en)
*
|
2011-11-09 |
2013-05-16 |
Children's Cancer Institute Australia for Medical Research |
Cancer treatment
|
CA2859744A1
(en)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Surrogate binding proteins
|
US20150011736A1
(en)
|
2012-01-20 |
2015-01-08 |
Sea Lane Biotechnologies, Llc |
Binding molecule conjugates
|
CN104254778A
(zh)
|
2012-02-10 |
2014-12-31 |
西雅图遗传学公司 |
Cd30+癌症的检测和治疗
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
CA3131619A1
(en)
|
2012-05-15 |
2013-11-21 |
Seagen Inc. |
Self-stabilizing linker conjugates
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
KR102427777B1
(ko)
|
2012-06-26 |
2022-08-01 |
델 마 파마슈티컬스 |
디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
|
EP2872218A4
(en)
*
|
2012-07-13 |
2016-07-06 |
Univ Pennsylvania |
COMPOSITIONS AND METHODS FOR REGULATING T CAR LYMPHOCYTES
|
PT2692865E
(pt)
|
2012-07-30 |
2015-02-06 |
Nbe Therapeutics Llc |
Identificação mediada por transposição de proteínas funcionais ou de ligação específicas
|
WO2014031875A1
(en)
|
2012-08-23 |
2014-02-27 |
Seattle Genetics, Inc. |
Treatment of sickle cell disease and inflammatory conditions
|
CN109369808B
(zh)
|
2012-08-24 |
2023-11-07 |
加利福尼亚大学董事会 |
用于治疗ror1癌症并抑制转移的抗体和疫苗
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
NO2789793T3
(US07794700-20100914-C00152.png)
*
|
2012-10-24 |
2018-01-27 |
|
|
MY169147A
(en)
|
2012-10-24 |
2019-02-18 |
Polytherics Ltd |
Drug-protein conjugates
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
EP2928503B1
(en)
|
2012-12-10 |
2019-02-20 |
Mersana Therapeutics, Inc. |
Conjugates of auristatin compounds
|
JP6449777B2
(ja)
|
2012-12-21 |
2019-01-09 |
シアトル ジェネティックス, インコーポレイテッド |
抗ntb−a抗体ならびに関連する組成物および方法
|
JP6444902B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びその結合体
|
EP2970491A4
(en)
*
|
2013-03-15 |
2016-11-23 |
Alper Biotech Llc |
MONOCLONAL ANTIBODIES AGAINST EGFR AND USES THEREOF
|
EP2777714A1
(en)
|
2013-03-15 |
2014-09-17 |
NBE-Therapeutics LLC |
Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
|
TWI654206B
(zh)
*
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
JP2016519684A
(ja)
|
2013-04-08 |
2016-07-07 |
デニス エム ブラウン |
準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物
|
EP4364809A2
(en)
*
|
2013-05-13 |
2024-05-08 |
Cellectis |
Cd19 specific chimeric antigen receptor and uses thereof
|
MX2021008464A
(es)
|
2013-10-15 |
2023-03-03 |
Seattle Genetics Inc |
Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
|
AU2014364812B2
(en)
|
2013-12-17 |
2017-05-25 |
Novartis Ag |
Cytotoxic peptides and conjugates thereof
|
CN112979786A
(zh)
|
2014-02-11 |
2021-06-18 |
西雅图基因公司 |
蛋白质的选择性还原
|
KR102647074B1
(ko)
|
2014-02-17 |
2024-03-14 |
씨젠 인크. |
친수성 항체-약물 컨쥬게이트
|
CN111499753B
(zh)
|
2014-03-03 |
2022-10-21 |
高雄医学大学 |
双功能抗体及其用途
|
JP2017518958A
(ja)
|
2014-03-19 |
2017-07-13 |
マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルMackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital |
免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
|
MX2016012259A
(es)
*
|
2014-04-07 |
2017-01-06 |
Seattle Genetics Inc |
Formulaciones estables para anticuerpos anti-cd19 y conjugados anticuerpo-farmaco.
|
AU2015244004A1
(en)
*
|
2014-04-08 |
2016-09-15 |
Seattle Genetics, Inc. |
Optimal dosing of a CD19-antibody drug conjugate
|
JP6681346B2
(ja)
|
2014-06-13 |
2020-04-15 |
ノバルティス アーゲー |
オーリスタチン誘導体およびその抱合体
|
ES2785551T3
(es)
|
2014-06-30 |
2020-10-07 |
Glykos Finland Oy |
Derivado de sacárido de una carga útil tóxica y sus conjugados con anticuerpos
|
WO2016036794A1
(en)
|
2014-09-03 |
2016-03-10 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
KR20170053648A
(ko)
|
2014-09-11 |
2017-05-16 |
시애틀 지네틱스, 인크. |
삼차 아민-함유 약물 물질의 표적화된 전달
|
AU2015320678B2
(en)
|
2014-09-23 |
2021-07-22 |
Genentech, Inc. |
Method of using anti-CD79b immunoconjugates
|
MD20170040A2
(ro)
|
2014-09-26 |
2017-07-31 |
Macrogenics Inc. |
Diacorpi monovalenţi bispecifici capabili de legare cu CD19 şi CD3 şi utilizarea acestora
|
MA41414A
(fr)
*
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
CN107406507A
(zh)
*
|
2015-02-12 |
2017-11-28 |
西雅图基因公司 |
使用cd19‑adc和长春新碱的组合疗法
|
US10722592B2
(en)
|
2015-03-18 |
2020-07-28 |
Seattle Genetics, Inc. |
CD48 antibodies and conjugates thereof
|
CN107660151B
(zh)
|
2015-05-26 |
2022-03-11 |
莫佛塞斯公司 |
抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
|
CN116726190A
(zh)
*
|
2015-06-20 |
2023-09-12 |
杭州多禧生物科技有限公司 |
澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
|
WO2017004330A1
(en)
|
2015-06-30 |
2017-01-05 |
Seattle Genetics, Inc. |
Anti-ntb-a antibodies and related compositions and methods
|
MX2018002241A
(es)
|
2015-08-21 |
2018-03-23 |
Morphosys Ag |
Combinaciones y sus usos.
|
US11149059B2
(en)
*
|
2015-09-08 |
2021-10-19 |
Waters Technologies Corporation |
Multidimensional chromatography method for analysis of antibody-drug conjugates
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
CN108290939B
(zh)
|
2015-10-16 |
2023-01-13 |
纽约市哥伦比亚大学理事会 |
用于抑制谱系特异性抗原的组合物和方法
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
AU2016363013B2
(en)
|
2015-12-04 |
2022-03-10 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
IL311107A
(en)
|
2016-02-17 |
2024-04-01 |
Seagen Inc |
BCMA antibodies and their use for the treatment of cancer and immune disorders
|
US11027021B2
(en)
|
2016-03-15 |
2021-06-08 |
Seagen Inc. |
Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
|
KR102626498B1
(ko)
|
2016-03-25 |
2024-01-19 |
씨젠 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
AU2017244108B2
(en)
*
|
2016-03-29 |
2021-03-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
CN109313194B
(zh)
|
2016-05-30 |
2022-11-04 |
莫佛塞斯公司 |
预测cd19抗体治疗在患者中的治疗益处的方法
|
PT3475303T
(pt)
|
2016-06-27 |
2021-06-25 |
Morphosys Ag |
Formulações de anticorpos anti-cd19
|
IL299099A
(en)
|
2016-06-27 |
2023-02-01 |
Univ California |
Combinations of cancer treatments
|
WO2018017928A1
(en)
*
|
2016-07-22 |
2018-01-25 |
Seattle Genetics, Inc. |
Combination therapy using a cd19-adc and rchp
|
MX2019001302A
(es)
|
2016-08-09 |
2019-06-12 |
Seattle Genetics Inc |
Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
EP3525829A1
(en)
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
CN109843334A
(zh)
|
2016-10-18 |
2019-06-04 |
西雅图基因公司 |
烟酰胺腺嘌呤二核苷酸补救途径抑制剂的靶向递送
|
RS62036B1
(sr)
|
2016-10-28 |
2021-07-30 |
Morphosys Ag |
Kombinacija anti cd19 antitela sa bcl-2 inhibitorom i njihova upotreba
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
CN116672463A
(zh)
*
|
2017-02-17 |
2023-09-01 |
浙江特瑞思药业股份有限公司 |
靶向cd20抗体偶联药物的制备方法、抗体偶联药物及其用途
|
CN110352074A
(zh)
|
2017-02-28 |
2019-10-18 |
西雅图遗传学公司 |
用于偶联的半胱氨酸突变抗体
|
JP7386082B2
(ja)
|
2017-02-28 |
2023-11-24 |
ブイオーアール バイオファーマ インコーポレーテッド |
系統特異的タンパク質の阻害のための組成物および方法
|
CA3056134A1
(en)
|
2017-03-24 |
2018-09-27 |
Seattle Genetics, Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
US11344578B2
(en)
|
2017-04-19 |
2022-05-31 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
TW201904613A
(zh)
|
2017-04-27 |
2019-02-01 |
美商西雅圖遺傳學公司 |
季鹼化菸鹼醯胺腺二核苷酸補救合成抑制劑結合物
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
SG11201909715VA
(en)
|
2017-05-31 |
2019-11-28 |
Morphosys Ag |
Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
|
JP7279011B2
(ja)
|
2017-07-10 |
2023-05-22 |
インターナショナル-ドラッグ-ディベロップメント-バイオテック |
抗cd20抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗cd19抗体を用いるb細胞悪性の治療
|
CN111032676A
(zh)
|
2017-08-10 |
2020-04-17 |
大日本住友制药株式会社 |
包含哈米特林衍生物的抗体药物复合物
|
CA3072500A1
(en)
*
|
2017-08-10 |
2019-02-14 |
Sumitomo Dainippon Pharma Co., Ltd. |
Hemiasterlin derivatives and antibody-drug conjugates including same
|
EP3684820A4
(en)
*
|
2017-09-21 |
2021-05-26 |
Wuxi Biologics (Cayman) Inc. |
NOVEL ANTI-CD19 ANTIBODIES
|
JP7356727B2
(ja)
|
2017-10-12 |
2023-10-05 |
慶應義塾 |
アクアポリン3(aqp3)の細胞外ドメインに特異的に結合する抗aqp3モノクローナル抗体、及びその使用
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
EP3717518A1
(en)
|
2017-12-01 |
2020-10-07 |
Seattle Genetics, Inc. |
Humanized anti-liv1 antibodies for the treatment of breast cancer
|
US11180552B2
(en)
|
2017-12-01 |
2021-11-23 |
Seagen Inc. |
CD47 antibodies and uses thereof for treating cancer
|
WO2019119822A1
(en)
*
|
2017-12-23 |
2019-06-27 |
Uwell Biopharma Inc. |
Pharmaceutical chimeric receptor composition and method thereof
|
MA52135A
(fr)
|
2018-03-23 |
2021-01-27 |
Seagen Inc |
Utilisation de conjugués anticorps-médicament comprenant des agents de rupture de tubuline pour traiter une tumeur solide
|
CN113286616A
(zh)
|
2018-05-23 |
2021-08-20 |
Adc治疗有限公司 |
分子佐剂
|
CN112512587A
(zh)
|
2018-08-06 |
2021-03-16 |
第一三共株式会社 |
抗体药物缀合物和微管蛋白抑制剂的组合
|
KR20220036908A
(ko)
|
2018-08-28 |
2022-03-23 |
보르 바이오파마 인크. |
유전자 조작된 조혈 줄기 세포 및 그의 용도
|
US20220098320A1
(en)
*
|
2019-02-01 |
2022-03-31 |
Memorial Sloan Kettering Cancer Center |
Senolytic car-t cells targeting upar, a cell surface and secreted senescence biomarker
|
AU2020219732A1
(en)
|
2019-02-05 |
2021-08-05 |
Seagen Inc. |
Anti-CD228 antibodies and antibody-drug conjugates
|
JP7479302B2
(ja)
|
2019-02-13 |
2024-05-08 |
住友ファーマ株式会社 |
ヘミアスタリン誘導体とその抗体薬物複合体
|
WO2020213084A1
(en)
|
2019-04-17 |
2020-10-22 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
CN114072424A
(zh)
|
2019-05-03 |
2022-02-18 |
莫佛塞斯公司 |
具有有限数量的nk细胞的患者中的抗cd19疗法
|
CN110128551A
(zh)
*
|
2019-06-05 |
2019-08-16 |
上海科弈药业科技有限公司 |
一种针对cd19+肿瘤的多功能融合蛋白及其应用
|
WO2020247574A1
(en)
|
2019-06-05 |
2020-12-10 |
Seattle Genetics, Inc. |
Methods of purifying masked antibodies
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
WO2021016233A1
(en)
|
2019-07-22 |
2021-01-28 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
JP2022550816A
(ja)
|
2019-10-04 |
2022-12-05 |
シージェン インコーポレイテッド |
抗pd-l1抗体および抗体-薬物コンジュゲート
|
JP2022550435A
(ja)
|
2019-10-04 |
2022-12-01 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
組換えaavの改善された治療的使用のための方法
|
MX2022005031A
(es)
|
2019-10-31 |
2022-07-27 |
Morphosys Ag |
Terapia anti cumulo de diferenciacion 19(cd19) en combinacion con lenalidomida para el tratamiento de leucemias o linfomas.
|
MX2022005033A
(es)
|
2019-10-31 |
2022-09-09 |
Morphosys Ag |
Terapia combinada antitumoral que comprende un anticuerpo anti grupo de diferenciación 19 (cd19) y linfocitos t gamma delta.
|
WO2021119551A1
(en)
*
|
2019-12-11 |
2021-06-17 |
Cullinan Oncology, Inc. |
Anti-cd19 antibodies and multi-specific binding proteins
|
CN115916816A
(zh)
*
|
2019-12-11 |
2023-04-04 |
库利南肿瘤股份有限公司 |
抗血清白蛋白抗体
|
WO2021178253A1
(en)
*
|
2020-03-03 |
2021-09-10 |
Systimmune, Inc. |
Anti-cd19 antibodies and methods of using and making thereof
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技(香港)有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
CA3176248A1
(en)
|
2020-04-10 |
2021-10-14 |
Seagen Inc. |
Charge variant linkers
|
EP4168449A1
(en)
|
2020-06-22 |
2023-04-26 |
MorphoSys AG |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint
|
TW202221034A
(zh)
|
2020-08-04 |
2022-06-01 |
美商西根公司 |
抗cd228抗體和抗體-藥物共軛體
|
JP2023543026A
(ja)
|
2020-09-28 |
2023-10-12 |
シージェン インコーポレイテッド |
がんの処置のためのヒト化抗liv1抗体
|
EP4225794A1
(en)
|
2020-10-06 |
2023-08-16 |
Xencor, Inc. |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
EP4240415A1
(en)
|
2020-11-08 |
2023-09-13 |
Seagen Inc. |
Combination-therapy antibody drug conjugate with immune cell inhibitor
|
WO2022117799A2
(en)
|
2020-12-04 |
2022-06-09 |
Morphosys Ag |
Anti-cd19 combination therapy
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
IL308296A
(en)
*
|
2021-05-07 |
2024-01-01 |
Viela Bio Inc |
Use of anti-CD19 antibody to treat myasthenia gravis
|
EP4370211A1
(en)
|
2021-07-14 |
2024-05-22 |
Seagen Inc. |
Antibody masking domains
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
WO2023073645A1
(en)
|
2021-10-29 |
2023-05-04 |
Takeda Pharmaceutical Company Limited |
Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
|
WO2023108102A1
(en)
*
|
2021-12-10 |
2023-06-15 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Anti-lcn-2 antibodies as a treatment for eye disorders
|
US20230381321A1
(en)
|
2022-03-17 |
2023-11-30 |
Seagan Inc., |
Camptothecin conjugates
|
WO2023245106A1
(en)
*
|
2022-06-16 |
2023-12-21 |
Abbvie Biotherapeutics Inc. |
Anti-cd19 antibody drug conjugates
|
WO2024038115A1
(en)
|
2022-08-17 |
2024-02-22 |
Morphosys Ag |
Therapy comprising anti-cd19 antibody and ezh2 modulators
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|
WO2024097816A1
(en)
|
2022-11-03 |
2024-05-10 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|